STAT1 and common variable immunodeficiency: Ruxolitinib (a JAK inhibitor) has demonstrated remarkable improvements in enteritis, natural killer cell function, and dysregulated T-cell polarization in patients with STAT1 mutations.15 Given the potential involvement of the gut-liver axis in the pathogenesis of CVID-associated NRH, ruxolitinib could be a promising treatment of NRH, although no studies have yet explored this hypothesis.